A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study on the Safety and Efficacy of GP681 Tablets in Patients With Influenza at High Risk of Influenza Complications
Latest Information Update: 28 Mar 2025
At a glance
- Drugs Suraxavir marboxil (Primary)
- Indications Influenza virus infections
- Focus Registrational; Therapeutic Use
- Sponsors Jiangxi Qingfeng Pharmaceutical
- 28 Mar 2025 New source identified and integrated (China Drug Trials CTR20242984)
- 04 Dec 2024 Status changed from not yet recruiting to recruiting.
- 30 Aug 2024 New trial record